Immutep (NASDAQ:IMMP) Share Price Passes Above 50 Day Moving Average of $2.49

Immutep Limited (NASDAQ:IMMP)’s share price crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $2.49 and traded as high as $2.74. Immutep shares last traded at $2.69, with a volume of 168,591 shares trading hands.

Immutep Stock Up 4.8 %

The stock has a 50 day moving average of $2.49 and a 200-day moving average of $2.26.

Institutional Investors Weigh In On Immutep

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in shares of Immutep by 15.4% in the 1st quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after acquiring an additional 4,700 shares in the last quarter. Meridian Wealth Management LLC grew its holdings in shares of Immutep by 3.6% during the fourth quarter. Meridian Wealth Management LLC now owns 322,450 shares of the biotechnology company’s stock worth $774,000 after purchasing an additional 11,250 shares in the last quarter. Finally, PFG Investments LLC bought a new position in shares of Immutep in the first quarter worth approximately $119,000. 2.32% of the stock is owned by hedge funds and other institutional investors.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.